Sign inCreate account

Report workspace tools

NCT01751269COMPLETEDanonymous

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Ascending Single and Multiple-Dose Study of the Safety, Tolerability, Pharmacokinetics of Intravenous RPX7009 in Healthy Adult Subjects.

Sponsor

Source record

Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)

Phase

Source record

PHASE1

Modality

AI-normalized

small molecule

Target

AI-normalized

RPX7009, Placebo

Indication / condition

AI-normalized

Healthy Volunteers

Intervention

Source record

RPX7009, Placebo

Source & freshness

Source record

NCT ID

NCT01751269

Original source

ClinicalTrials.gov

Source last updated

Jul 24, 2013

Ingested at

May 23, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT01751269

Title

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Ascending Single and Multiple-Dose Study of the Safety, Tolerability, Pharmacokinetics of Intravenous RPX7009 in Healthy Adult Subjects.

Sponsor

Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)

Status

COMPLETED

Phase

PHASE1

Condition raw

Healthy Volunteers

Condition normalized

Healthy Volunteers

Modality raw

antimicrobial resistance

Modality normalized

small molecule

Target raw

RPX7009, Placebo

Target normalized

RPX7009, Placebo

Interventions

RPX7009, Placebo

Public preview

Source record

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Ascending Single and Multiple-Dose Study of the Safety, Tolerability, Pharmacokinetics of Intravenous RPX7009 in Healthy Adult Subjects. is a PHASE1 clinical asset sponsored by Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company) in Healthy Volunteers, Bacterial Infections. SEO and diligence focus: RPX7009, Placebo, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Ascending Single and Multiple-Dose Study of the Safety, Tolerability, Pharmacokinetics of Intravenous RPX7009 in Healthy Adult Subjects.

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT01751269

Status

COMPLETED

Phase

PHASE1

Sponsor

Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)

Executive brief

Investment-Ready Snapshot

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Ascending Single and Multiple-Dose Study of the Safety, Tolerability, Pharmacokinetics of Intravenous RPX7009 in Healthy Adult Subjects. is a PHASE1 clinical asset sponsored by Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company) in Healthy Volunteers, Bacterial Infections. SEO and diligence focus: RPX7009, Placebo, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedJul 24, 2013
Internal syncJun 05, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT01751269

Indication

Healthy Volunteers

Modality

small molecule

Target

RPX7009, Placebo

Intervention

RPX7009, Placebo

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.